Clinical trials: B-Cell Acute Lymphoblastic Leukaemia
Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
The purpose of the study was to understand the effectiveness and safety of the study medicine called Inotuzumab ozogamicin (InO) in patients with B-cell ALL in whom the disease occurred again after the last treatment.
- Trial name
- NCT05597085
- Testing
- Inotuzumab Ozogamicin
- Where
- 5 sites in India
- Volunteers
- 32 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Study of @neWorld: A Virtual Community for Children With Cancer
RATIONALE: Using an Internet Web site that enables children with cancer to interact online with classmates, participate in classroom activities, get easy-to-read medical information, and chat with family members, medical staff…
- Conditions
- Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00070421
- Testing
- complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care
- Where
- United States
- Sponsor
- Leap of Faith Technologies
Acute Lymphoblastic Leukemia
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.
- Trial name
- NCT02010931
- Where
- 10 sites in Czechia, France and 6 more
- Volunteers
- 310 people
- Sponsor
- Amgen
B-cell Acute Lymphoblastic Leukemia
SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and pharmacokinetic profile of SNC116 in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
- Trial name
- NCT07830238
- Testing
- SNC116
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Leukemia
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation
- Trial name
- NCT04336501
- Testing
- IM19 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects
This is a single arm, open-label, uni-center, phase I/II study to determine the safety and efficacy of an experimental therapy called BinD19 cells in patients with B-cell acute lymphoblastic leukemia or lymphoma, who are…
- Conditions
- Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed／Refractory B-cell Lymphoma
- Trial name
- NCT03156101
- Testing
- BinD19
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shenzhen BinDeBio Ltd.
B-ALL
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL
- Trial name
- NCT04781634
- Testing
- CD19 and CD22 targeted prime CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.
- Conditions
- Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04888468
- Testing
- pCAR-19B cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
B-ALL
Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD22 CAR-T cell in the treatment of recurrent or refractory B-ALL
- Trial name
- NCT04546906
- Testing
- CD22 CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Acute Lymphoblastic Leukemia
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2…
- Trial name
- NCT04524455
- Testing
- Blinatumomab, AMG 404, Dexamethasone Premedication
- Where
- 19 sites in United States, Australia and 7 more
- Volunteers
- 17 people
- Sponsor
- Amgen
Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder)
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
- Trial name
- NCT05348889
- Testing
- 1A46 Injection
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Chimagen Biosciences, Ltd
Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL)
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
This was a Retrospective cohort study based on the PMSI data source
- Trial name
- NCT05349201
- Testing
- KYMRIAH, YESCARTA
- Where
- United States
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
This was a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who were…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
- Trial name
- ENSIGN (NCT02228096)
- Testing
- CTL019 T-cells
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL)
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL), Large B-cell Lymphoma
- Trial name
- CARLA (NCT06593145)
- Testing
- FCTX-CL19-1 (Tarcidomgen Kimleucel)
- Where
- 2 sites in Poland
- Volunteers
- 6 people
- Sponsor
- FamiCordTx
B-cell Acute Lymphocytic Leukemia
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
- Trial name
- NCT03064269
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04690595
- Testing
- BAFFR-CAR T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- PeproMene Bio, Inc.
Leukemia, B-Cell
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
The purpose of the study is to determine the maximum tolerated dose (MTD) in patients with acute lymphoblastic leukemia (ALL) and to determine the safety and tolerability of increasing doses and different infusion times of AFM11…
- Trial name
- NCT02848911
- Testing
- AFM11
- Where
- 12 sites in Austria, Czechia and 3 more
- Volunteers
- 17 people
- Sponsor
- Affimed GmbH
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
The primary objective is to evaluate the rate of complete remission/complete remission with partial hematological recovery (CRh*) in adults with relapsed/refractory Philadelphia chromosome positive (Ph+) B-precursor acute…
- Trial name
- NCT02000427
- Testing
- Blinatumomab
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 45 people
- Sponsor
- Amgen
CD19-positive, Acute Lymphoblastic Leukemia
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia.
- Trial name
- NCT03798509
- Testing
- Human CD19 targeted T Cells Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.